Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.

"Conflict of interest statement: J.P. Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from AbbVie, Advia, Allergan, Almirall, AstraZeneca, Biogen, Casen Fleet, Casen Recordati, Celgene, Chiesi, Diasorin, Dr. Falk Pharma GmbH, Faes Farma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, Hospira, Kern Pharma, Mayoly, MSD, Nycomed, Otsuka Pharmaceutical, Pfizer, Roche, Sandoz, Shire Pharmaceuticals, Takeda, Tillotts Pharma AG and Vifor Pharma.: M. Chaparro has served as a speaker, or has received research or education funding from AbbVie, Dr. Falk Pharma GmbH, Ferring Pharmaceuticals, Janssen, Hospira, MSD, Pfizer, Shire Pharmaceuticals, Takeda and Tillotts Pharma AG.: M. Barreiro-de Acosta has served as a speaker, a consultant and advisory member for or has received research funding from AbbVie, AMGEN, Chiesi, Dr. Falk Pharma GmbH, Faes Farma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, Hospira, Kern Pharma, MSD, Otsuka Pharmaceuticals, Pfizer, Sandoz, Shire Pharmaceuticals, Takeda and Tillotts Pharma AG.: E. Domènech has served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Celgene, Ferring Pharmaceuticals, Gebro Pharma GmbH, Grifols, Janssen, Kern Pharma, MSD, Otsuka Pharmaceuticals, Pfizer, Shire Pharmaceuticals, Takeda, Thermofisher and Tillots Pharma AG.: M. Esteve reports personal fees from Janssen, Menarini, Pfizer, Takeda and Tillots Pharma AG, and grants from AbbVie and MSD, outside the submitted work.: P. Nos has participated in educational activities, research projects and scientific meetings sponsored by AbbVie, Faes Farma, Ferring Pharmaceuticals, Janssen, MSD, Otsuka, Takeda and Tillots Pharma AG.: J. Panés has received consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Celltrion, Ferring Pharmaceuticals, Genentech, GlaxoSmithKline, Janssen, MSD, Nestle, Oppilan, Progenity, Pfizer, Robarts, Roche, Second Genome, Takeda, Theravance, TiGenix and Topivert; speaker fees from AbbVie, Biogen, Ferring Pharmaceuticals, Janssen, MSD, Shire Pharmaceuticals, Takeda and Tillotts Pharma AG; and research funding from AbbVie and MSD."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this work was supported by the Instituto de Salud Carlos III (PI15/00560). Project financed with FEDER funds."

"Clinical trial reference number: EudraCT 2015-001410-10"